Recruiting PHASE1 INTERVENTIONAL 1-arm NCT05136846

Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer

A Phase I Trial Targeting Mitochondrial Metabolism With Papaverine in Combination With Chemoradiation for Stage II-III Non-Small Cell Lung Cancer

Sponsor: National Cancer Institute (NCI)

Conditions Locally Advanced Lung Non-Small Cell Carcinoma Stage II Lung Cancer AJCC v8 Stage IIA Lung Cancer AJCC v8 Stage IIB Lung Cancer AJCC v8 Stage III Lung Cancer AJCC v8 Stage IIIA Lung Cancer AJCC v8 Stage IIIB Lung Cancer AJCC v8 Stage IIIC Lung Cancer AJCC v8 Unresectable Lung Non-Small Cell Carcinoma

Interventions Biospecimen Collection Carboplatin Computed Tomography Durvalumab Hypofractionated Radiation Therapy Magnetic Resonance Imaging Magnetic Resonance Imaging of the Brain with and without Contrast Paclitaxel Papaverine Pemetrexed Positron Emission Tomography Radiation Therapy

Updated 10 times since 2021 Last updated: May 29, 2025 Started: Dec 6, 2021 Primary completion: Dec 31, 2026 Completion: Dec 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Locally Advanced Lung Non-Small Cell Carcinoma and Stage II Lung Cancer AJCC v8 and is currently actively recruiting participants. National Cancer Institute (NCI) leads this study, which shows 10 recorded versions since 2021 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

10 versions recorded

Jul 2025 — Present [monthly]

Recruiting PHASE1
Jun 2025 — Jul 2025 [monthly]

Recruiting PHASE1
Mar 2025 — Jun 2025 [monthly]

Recruiting PHASE1
Sep 2024 — Mar 2025 [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1

▶ Show 5 earlier versions

Jan 2024 — Jul 2024 [monthly]

Recruiting PHASE1
Apr 2023 — Jan 2024 [monthly]

Recruiting PHASE1
May 2022 — Apr 2023 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Feb 2022 — May 2022 [monthly]

Not Yet Recruiting PHASE1
Dec 2021 — Feb 2022 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
Ohio State University Comprehensive Cancer Center

Data source: Ohio State University Comprehensive Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Columbus, United States
• Duarte, United States